Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750 million aggregate principal amount of 0.750% senior notes due 2027 and €650 million aggregate principal amount of 1.250% senior notes due 2031. AbbVie intends to use the net proceeds from the offerings to repay its 0.375% senior notes due 2019 and/or for general corporate purposes.

Headquartered in Chicago, Illinois, AbbVie is a global research-based biopharmaceutical company that develops and markets advanced therapies that address some of the world’s most complex and serious diseases. AbbVie products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus; neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Stephen A. Byeff, Michael Despres and Roman Shapurko. The tax team included partner Michael Farber and associate Liang Zhang. Partner David R. Bauer and associate Jay Frankel and Hilary Smith provided intellectual property and technology advice. Counsel David A. Zilberberg and associate Rachel Hoberman provided environmental advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post